SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 76923.00
87.22 (0.11%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
61	Cipla Ltd.	Q V PT	1,13,894 Large Cap	1,434.80 (1.77%)	33.79	3.24	8.01	10.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
62	Emcure Pharmaceuticals Ltd.	Q V+ PT	36,490 Small Cap	1,945.60 (1.14%)	49.78	9.83	13.02	9.98	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
63	Pfizer Ltd.	Q V PT	21,456 Small Cap	4,706.75 (0.35%)	29.7	5.11	2.39	8.89	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
64	Thyrocare Technologies Ltd.	Q V+ PT	9,287 Small Cap	592.20 (1.49%)	52.68	14.76	10.88	8.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
65	Themis Medicare Ltd.	Q V PT	995 Small Cap	107 (-0.97%)	N/A	3.71	15.00	7.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
66	Sigachi Industries Ltd.	Q V+ PT	991 Small Cap	25.43 (-1.93%)	N/A	2.08	24.05	7.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
67	Gland Pharma Ltd.	Q V PT	40,049 Small Cap	2,458 (1.24%)	30.82	3.7	9.35	7.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
68	Alivus Life Sciences Ltd.	Q V PT	13,876 Small Cap	1,120.45 (-0.89%)	24.58	4.16	9.20	6.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
69	GPT Healthcare Ltd.	Q V PT	1,361 Small Cap	166 (0.09%)	32.23	5.05	14.25	6.47	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
70	Bliss GVS Pharma Ltd.	Q V+ PT	4,898 Small Cap	450.60 (-2.26%)	50.56	4.28	9.41	4.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
71	Divis Laboratories Ltd.	Q V+ PT	1,96,881 Large Cap	7,455.70 (0.53%)	76.67	11.75	8.67	4.44	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
72	Aarti Drugs Ltd.	Q V PT	3,752 Small Cap	409.40 (-0.40%)	19.25	2.42	5.74	4.42	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
73	Eris Lifesciences Ltd.	Q V PT	19,400 Small Cap	1,393.10 (-0.49%)	31.32	4.97	21.92	3.58	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
74	Bajaj Healthcare Ltd.	Q V PT	1,078 Small Cap	319.95 (-0.05%)	46.8	1.97	5.76	2.91	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
75	Viyash Scientific Ltd.	Q V PT	11,352 Small Cap	255.65 (-1.62%)	64.03	4.2	20.23	2.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
76	Metropolis Healthcare Ltd.	Q V PT	11,981 Small Cap	590.30 (2.17%)	63.05	7.92	9.22	2.10	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
77	Ipca Laboratories Ltd.	Q V+ PT	45,090 Mid Cap	1,768 (-0.52%)	39.81	5.65	7.35	1.36	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
78	FDC Ltd.	Q V PT	6,794 Small Cap	414.20 (-0.74%)	23.76	2.73	9.23	1.32	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
79	Syngene International Ltd.	Q V+ PT	16,710 Small Cap	408.85 (-1.23%)	54.8	3.58	9.45	1.26	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
80	Concord Biotech Ltd.	Q V PT	13,150 Small Cap	1,254.55 (-0.19%)	50.4	6.52	11.33	1.26	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
81	Hester Biosciences Ltd.	Q V PT	2,151 Small Cap	2,540 (0.45%)	41.29	5.58	6.98	0.80	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
82	Aster DM Quality Care Ltd.	Q V+ PT	70,000 Mid Cap	804.55 (0.19%)	180.35	14.2	-13.71	0.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
83	Onesource Specialty Pharma Ltd.	Q V PT	19,375 Small Cap	1,744.75 (3.26%)	406.87	3.23	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
84	Aarti Pharmalabs Ltd.	Q V+ PT	6,217 Small Cap	680.95 (-0.69%)	35.29	3.14	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
85	Dr. Agarwals Health Care Ltd.	Q V PT	15,076 Small Cap	487.60 (2.53%)	113.19	7.44	26.38	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
86	IOL Chemicals And Pharmaceuticals Ltd.	Q V+ PT	4,453 Small Cap	149.60 (-1.38%)	32.35	2.48	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
87	Sun Pharma Advanced Research Company Ltd.	Q V+ PT	6,974 Small Cap	211 (-1.81%)	4.49	5.23	49.34	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
88	Panacea Biotec Ltd.	Q V+ PT	2,654 Small Cap	418.10 (-3.51%)	N/A	9.3	-8.75	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
89	Nephrocare Health Services Ltd.	Q V+ PT	6,853 Small Cap	689.80 (1.22%)	N/A	7.19	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
90	Fischer Medical Ventures Ltd.	Q V PT	2,464 Small Cap	37.46 (-0.50%)	N/A	7.89	96.10	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Onesource Specialty	1,744.75	3.26%
Dr. Agarwals Health	487.60	2.53%
Metropolis Health.	590.30	2.17%
Laurus Labs	1,745.85	1.84%
Cipla	1,434.80	1.77%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Acutaas Chemicals	3,121.05	-7.35%
Senores Pharmaceutic	1,317.55	-6.66%
Suven Life Sciences	297.85	-4.44%
Wanbury	318.55	-3.82%
Panacea Biotec	418.10	-3.51%

News about Top Pharma Companies in India

Jul, 2026

Cipla gets USFDA’s approval for Generic Advair Diskus

The product is a therapeutically equivalent version of Advair Diskus, a widely prescribed combination therapy indicated for the treatment of asthma and COPD

Jul, 2026

Ipca Laboratories informs about board meeting

Pursuant to Regulation 29 read with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ipca Laboratories has informed that a meeting of the Board of Directors of the Company will be held on Thursday, 13th August, 2026, to consider and take on record the standalone and consolidated unaudited financial results of the Company for the 1st quarter ended 30th June, 2026 of the financial year 2026-27. Further, with reference to the above meeting of the Board of Directors, it has already informed vide its letter dated 22nd June, 2026 that the trading window for dealing in the securities of the Company by the Insiders as defined under the SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed with effect from 1st July, 2026 and until 48 hours after the declaration of the Company’s unaudited financial results for the 1st quarter ended 30th June, 2026 i.e., till 15th August, 2026.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Gland Pharma informs about board meeting

Gland Pharma has informed that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026, inter alia, to consider and approve Unaudited Standalone and Consolidated Financial results of the Company for the quarter ended June 30, 2026.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Onesource Specialty - Quaterly Results

A decent increase of about 39.08% in the sales to Rs. 4464.71 millions was observed for the quarter ended June 2026. The sales figure stood at Rs. 3210.12 millions during the year-ago period.The company almost doubled its revenue to Rs. 512.25 millions from Rs. 248.15 millions in the quarter ended June 2026.Operating Profit saw a handsome growth to 1179.19 millions from 851.30 millions in the quarter ended June 2026.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	4464.71	3210.12	39.08	4464.71	3210.12	39.08	14053.81	12995.89	8.14
Other Income	37.87	52.55	-27.94	37.87	52.55	-27.94	150.08	176.82	-15.12
PBIDT	1179.19	851.30	38.52	1179.19	851.30	38.52	2840.01	3869.57	-26.61
Interest	305.17	270.31	12.90	305.17	270.31	12.90	1205.76	1616.50	-25.41
PBDT	874.02	580.99	50.44	874.02	580.99	50.44	1580.05	1130.57	39.76
Depreciation	361.77	332.84	8.69	361.77	332.84	8.69	1367.95	1345.12	1.70
PBT	512.25	248.15	106.43	512.25	248.15	106.43	212.10	-214.55	-198.86
TAX	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-414.55	0.00
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-414.55	0.00
PAT	512.25	248.15	106.43	512.25	248.15	106.43	212.10	200.00	6.05
Equity	114.64	114.46	0.16	114.64	114.46	0.16	114.62	114.43	0.17
PBIDTM(%)	26.41	26.52	-0.41	26.41	26.52	-0.41	20.21	29.78	-32.13

Jul, 2026

Panacea Biotec informs about disclosure

Pursuant to Regulation 30 read with Para B of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI LODR Regulations’), Panacea Biotec has informed that the Company’s wholly owned subsidiary, Panacea Biotec Pharma (‘PBPL’), has received a Show Cause Notice dated July 23, 2026, from the office of the Assistant Commissioner, Goods and Services Tax (‘GST’), Delhi under Section 73 of Delhi Goods & Services Tax / Central Goods & Services Tax Act & Rules, 2017 alleging total tax liability of ?4.06 Crore including interest, tax and penalty, on account of alleged excess claim of Input Tax Credit in the Annual Return filed for the Financial Year 2022-23. The requisite details as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and Industry Standards on Regulation 30 of SEBI LODR Regulations, are annexed as Annexure A.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Cipla surges despite reporting 39% fall in Q1 consolidated net profit

Consolidated total income of the company increased by 1.58% to Rs 7,330.18 crore in Q1FY27

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Max Healthcare Institute Ltd.	1,08,476 Crore
2	Yatharth Hospital & Trauma Care Services Ltd.	8,132 Crore
3	3B Blackbio Dx Ltd.	1,112 Crore
4	Artemis Medicare Services Ltd.	4,408 Crore
5	Novartis India Ltd.	4,023 Crore
6	Jupiter Life Line Hospitals Ltd.	10,728 Crore
7	Jagsonpal Pharmaceuticals Ltd.	1,511 Crore
8	Neuland Laboratories Ltd.	24,345 Crore
9	Kwality Pharmaceuticals Ltd.	2,815 Crore
10	Rainbow Childrens Medicare Ltd.	15,076 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	27,893	59,102	38.08	12.45	26.07	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,922	1,90,832	88.21	22.69	45.79	29.04
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	20.66	4.92	11.95	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,358	42,278	40.04	9.35	27.05	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,631	67,124	30.72	4.80	22.28	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,746	92,623	105
Sai Life Sciences Ltd. (S)	Very Good	1,291	27,347	53.73
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,922	1,90,832	39.27
Aurobindo Pharma Ltd. (M)	Very Good	1,553	89,115	38.01
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	23.52
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,291	27,347	80.08	10.90	42.11	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,358	42,278	40.04	9.35	27.05	13.54
Mankind Pharma Ltd. (M)	Very Good	2,587	1,05,357	51.71	6.44	32.38	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,523	21.93	4.25	13.45	13.52
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	20.66	4.92	11.95	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	20.66	4.92	11.95	32.37
Abbott India Ltd. (M)	Very Good	27,893	59,102	38.08	12.45	26.07	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,146	96,063	29.81	2.52	15.31	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,523	21.93	4.25	13.45	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,984	4,73,509	41.25	5.67	23.65	14.41

You have 9 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Cipla gets USFDA’s approval for Generic Advair Diskus

Ipca Laboratories informs about board meeting

Gland Pharma informs about board meeting

Onesource Specialty - Quaterly Results

Panacea Biotec informs about disclosure

Cipla surges despite reporting 39% fall in Q1 consolidated net profit

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.